REG - Arecor Therapeutics - Arecor Granted Patents in India and the US

Arecor TherapeuticsAnnouncement

16/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230216:nRSP0726Qa&default-theme=true

RNS Number : 0726Q  Arecor Therapeutics PLC  16 February 2023

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY
FORMULATIONS OF DIFFERENTIATED BIOPHARMACEUTICAL PRODUCTS

 

-   Patents further strengthen Group's extensive patent portfolio protecting
its proprietary diabetes portfolio and demonstrate potential of innovative
Arestat™ technology in development of enhanced formulations of high value
biologics

 

Cambridge, UK, 16 February 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
is pleased to announce that the Indian Patent Office has granted a patent
(IN412485) protecting novel formulations of the Group's proprietary insulin
products, AT247 and AT278, until 2038. In addition, the United States Patent
and Trademark Office has granted two patents (US11534402 and US11534403)
protecting the Group's novel formulations of high-concentration adalimumab
until 2038.

 

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "As we continue
to successfully apply our Arestat(™) technology to develop enhanced
pharmaceutical products, it is crucial that we maintain strong IP protection,
both for the fundamental features of our technology and for the final drug
products. These three recently granted patents demonstrate the continued
strength of Arecor's IP portfolio, providing further protection for our
differentiated in-house development products AT247 and AT278, as well as
within competitive IP areas such as that surrounding adalimumab formulations.
These patents further reinforce the strength of Arecor's technology and
expertise in valuable commercial areas such as inflammatory diseases and
diabetes."

 

The patent granted in India protects the formulations of Arecor's clinical
insulin candidates, AT247 and AT278, that have been designed to significantly
accelerate insulin absorption post injection across a range of insulin
concentrations and thus enable more effective management of blood glucose
levels for people living with diabetes, particularly around difficult to
manage mealtimes. The granted Indian patent is an important milestone in
Arecor's strategy to generate a strong protection through a combination of
both narrow and broad interrelated IP rights that cover the features of these
products, within key markets, adding to patents already granted in the US,
South Korea and Japan.

 

Adalimumab, sold by AbbVie under the brand name Humira®, has been a
blockbuster monoclonal antibody product since its launch in 2003, with the
market shifting to use the high concentration version in the last few years.
Formulating a high concentration version of adalimumab is technically
challenging and further complicated by a complex patent landscape surrounding
adalimumab formulations. Using its Arestat™ technology, Arecor has developed
novel formulations enabling a high-concentration adalimumab product (100 mg/mL
or higher) with excellent stability. The two granted US patents protect the
novel formulation space enabling these formulations and follow earlier,
similar patents, granted in Europe.

 

Arecor has invested in building a strong patent portfolio to protect the
Arestat™ technology platform and its proprietary pipeline products. The
Group's intellectual property (IP) portfolio currently comprises 36 patent
families, including >50 granted patents in Europe, the US and in other key
territories. The recently granted patents represent an important addition to
Arecor's extensive IP portfolio.

 

 

-ENDS-

 

 

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Lindsey Neville      Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

 

 

Notes to Editors

 

About Arestat™

Arecor's Arestat™ technology enables superior product profiles across a
broad range of therapies, including various types of biopharmaceuticals and
specialty hospital products. In addition to its internal portfolio of superior
proprietary products in diabetes and other indications, Arecor leverages the
Arestat™ technology in partnerships with leading pharmaceutical and
biotechnology companies to deliver enhanced formulations of their therapeutic
products under a technology licensing model.

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKPBNCBKDQBD